Introduction
Neuroblastoma, a tumor of the embryonic neural crest, has distinctly different outcomes that may be predicted by several well-established genetic factors as well as degree of differentiation. Patients with localized tumors (stages 1 and 2) comprising well-differentiated cells are treated primarily by surgical resection and have a 93% overall survival rate (Izbicki et al., 2003) . By contrast, children with metastatic tumors, comprising poorly differentiated cells (stage 4), respond transiently to therapy and have only a 10-30% survival rate (Look et al., 1991; Mora et al., 2001) . Among the characteristics associated with an unfavorable prognosis are two chromosomal abnormalities -(1) amplification of the Nmyc proto-oncogene (Brodeur et al., 1984) signaled cytogenetically by the presence of homogeneously staining regions (HSRs) or double minute chromosomes (DMs) (Brodeur and Seeger, 1986) and (2) deletion of all or a portion of the short arm of chromosome #1 (1p-) (Fong et al., 1989; Caron et al., 1995 Caron et al., , 1996 .
It has been proposed that the N-myc proto-oncogene is involved in maintaining the proliferative, undifferentiated state of cells during normal development and in neuroectodermal cancers (Cole and McMahon, 1999) . In the developing central nervous system, levels of Nmyc mRNA are high in mitotic neuroblasts, but decrease dramatically with differentiation into postmitotic neurons (Mugrauer et al., 1988) . Likewise, mice homozygous for null mutations of the N-myc gene die during embryonic development, presumably as a result of reduced neuronal cell number (Charron et al., 1992) . Multiple lines of evidence support the crucial role of Nmyc overexpression in neuroblastic tumor progression and/or maintenance of the malignant phenotype: (1) Nmyc amplification is found in about 30% of tumors (mostly stages 3 and 4) and is associated clinically with aggressive growth and poor response to therapy ; (2) targeted overexpression of N-myc in transgenic mice leads to the development of neuroblastoma tumors (Weiss et al., 1997) ; and (3) in neuroblastoma cell lines that amplify N-myc, malignant potential correlates directly with N-myc expression level and differentiation lineage (Spengler et al., 1997) .
Partial or complete deletion of the short (p) arm of one chromosome #1 homologue is observed in about 40% of neuroblastoma tumors (Fong et al., 1989; Schleiermacher et al., 1994) . At least two regions of deletion can be distinguished: a distal segment (bands 1p36.3-36.2), thought to be the location of a tumor suppressor gene, and a larger, more proximal (1p36-32) segment (Maris and Matthay, 1999) . Loss of the latter region correlates with N-myc amplification (Schleiermacher et al., 1994; Takeda et al., 1994; Bello et al., 1995; Caron et al., 1995) . Tumors with both the large 1p deletion and N-myc amplification define a subset of neuroblastoma with an especially poor prognosis (Maris et al., 1995; Caron et al., 1996) . Of interest in the present study, the ELAVL4 gene, encoding the HuD protein, has been mapped to 1p34, within this broad region of chromosome #1 (Muresu et al., 1994) .
HuD, one member of the Hu family of neuronalspecific RNA-binding proteins (Szabo et al., 1991) , binds to N-myc and appears to be one regulator of its expression in malignant neuroblasts (Chagnovich and Cohn, 1996; Lazarova et al., 1999) . Thus, reduction in the amount of HuD mRNA (and protein) following loss of one allele could result in marked reduction in steadystate levels of mature N-myc mRNA and protein. Since N-myc appears to be crucial for proliferation and survival of embryonic neuroblasts, decreased amounts of HuD protein would adversely affect cell survival. Cells with additional copies of N-myc genes would have higher levels of the oncoprotein and could quickly increase in frequency to become the dominant population because of their selective growth and survival advantage. In this scenario, deletion in the short arm of one chromosome #1, leading to haploinsufficiency of HuD, would precede and promote N-myc amplification. If true, introduction of HuD cDNA into cells and consequent elevation of its expression should reduce the selection pressure for retention of amplified N-myc genes and result in gene loss. Conversely, reduction in HuD, similar to the situation seen in tumors, by stable expression of antisense cDNA should increase selection pressure and lead to selection of cells with an increased number of N-myc genes (gain/amplification). Our experimental results are consistent with this hypothesis.
Results

Correlation of N-myc amplification with chromosome 1p loss
Initial studies examined the relationship between the incidence of N-myc amplification and deletion of the short arm of chromosome #1 in human neuroblastoma cell lines. Several previous studies have shown a strong correlation between these two abnormalities in human neuroblastoma tumors (Caron et al., 1995 (Caron et al., , 1996 . In all, 12 independent human neuroblastoma cell lines were assessed cytogenetically for the presence of N-myc amplification-associated chromosomal structures, HSRs or DMs, and for chromosome 1p deletion (Table 1) . With one exception, all cell lines that amplify N-myc show loss of some or all of the short arm of one chromosome #1 homologue. The shortest region of overlap in these lines extends from the end of the arm to band 1p34. The apparent exception, SMS-MSN, contains 100 copies of the N-myc gene/haploid genome (Reynolds et al., 1986 (Reynolds et al., , 1988 but has two #1 chromosomes that appear cytogenetically normal.
HuD gene copy number and expression level Of interest in the present study, the HuD gene was localized by Muresu et al. (1994) to band 1p34. We therefore assessed the gene copy number for HuD and for Hel-N1, a second member of the Hu family of neuronal-specific RNA-binding proteins that has been localized to chromosome 9p (Han et al., 1996) . Both Southern and multiplex polymerase chain reaction (PCR) analyses show that, whereas all neuroblastoma cell lines contain two copies of the Hel-N1 gene (per diploid cell), all N-myc-amplified cell lines -including SMS-MSN -have consistently lost one HuD allele ( Figure 1 , Table 2 , and data not shown). The finding by both PCR and Southern blot analyses of only one HuD gene in SMS-MSN suggests that this line has an interstitial deletion in the short arm of chromosome #1 which includes the HuD gene. It also strengthens the hypothesis that it is loss of one HuD allele, rather than loss of another gene on 1p, that correlates with N-myc amplification.
To determine the effect of loss of a single HuD allele on its level of expression, we analysed steady state RNA levels from N-myc amplified and nonamplified neuroblastic cell lines by Northern and RT-PCR analyses ( Figure 2 and Table 3 ). HuD expression is reduced B2.4-fold in N-myc-amplified cell lines that contain one HuD allele, relative to nonamplified cell lines, which have two copies. By contrast, Hel-N1 mRNA expression, although variable, is not significantly different among the lines and does not correlate with N-myc amplification status (data not shown). (Foley et al., 1991) .
h Three copies of chromosome #1 in a tetraploid karyotype.
Figure 1 Southern blot analysis of HuD gene copy number, relative to g-actin, from N-myc-nonamplified (lanes 1, 2) andamplified (lanes 3-11) human neuroblastoma cell lines. Lane, cell line: 1, SMS-LHN; 2, SH-SY5Y; 3, LA1-55n; 4, SMS-SAN; 5, CHP-234; 6, IMR-32; 7, SK-N-BE(1)n; 8, SMS-MSN; 9, SMS-KCN; 10, SMS-KAN; and 11, NBL-Wn.
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Modulation of N-myc gene copy number and mRNA expression in cells transfected with HuD We next determined whether replacement of HuD genes could affect N-myc amplification status and expression. BE(2)-M17 cells (an N-type cell line with amplified Nmyc genes in a chromosomally integrated HSR and HuD monozygosity) were transfected with an expression vector containing a sense cDNA for the entire coding region of the HuD gene or with vector alone. Six stable clones each of HuD-and vector-transfected cells were selected using 500 mg/ml of G418 and assayed for changes in Hu protein levels, HuD, Hel-N1 and N-myc mRNA levels, and HuD and N-myc gene copy numbers. As illustrated in Figure 3a and summarized in Table 4 , HuD-transfectants contain 9.6-fold more HuD cDNA than vector-transfected controls. While Hel-N1 mRNA levels are not changed, mean HuD mRNA levels are nearly fivefold higher in the HuD-transfected BE(2)-M17 clones as compared to vector-transfected controls (Table 4) . Hu protein amount in HuD-transfectants (determined with antiserum crossreacting with Hel-N1 and HuC proteins) is increased an average of 2.6-fold. Figure 2 Northern blot analysis of HuD expression, relative to that of g-actin, in nonamplified (lanes 1, 2, 10) and N-myc-amplified (lanes 3-9) human neuroblastoma N-type cell lines and clones. Lanes 1-6 and 7-10 are from two separate blots. The two bands correspond to the two major splice variants of HuD. Lane, cell line: 1, SH-SY5Y; 2, SMS-LHN; 3, SMS-MSN; 4, NBL-Wn; 5, LA1-55n; 6, SK-N-BE(1)n; 7, SMS-KAN; 8, SMS-KCN; 9, SMS-SAN; and 10, SH-SY5Y. Amplified lines show reduced HuD expression compared to nonamplified lines. Gene copy number, determined by PCR and expressed as mean7s.e.m. relative to GAPD. Mean gene copy number for the three vector clones was set at 1.0 for HuD and at 100 for N-myc. c mRNA expression, determined by RT-PCR and expressed relative to b-actin, represents the mean7s.e.m. of 3-6 determinations. Mean values for vector clones are set equal to mean gene copy number: 1.0 for HuD, 2.0 for Hel-N1, and 100 for N-myc expression.
The HuD-and vector-transfected clones do not differ from each other or from the parental cell lines in morphology or in their levels of the neuronal marker proteins chromogranin A or neurofilament 160 (data not shown). Our earlier finding -that HuD increases the efficiency of pre-mRNA processing and/or mRNA stability -had suggested that N-myc mRNA levels may remain high even with fewer N-myc genes. Indeed, analysis done after approximately 5 months in culture showed that N-myc expression is 1.9-fold higher in HuD-transfected BE(2)-M17 cells (Figure 3c and Table 4 ) despite an almost twofold decrease in N-myc gene copy number compared to vector controls ( Figure 3b , Table 4 ). These changes result in 3.6-fold more N-myc mRNA/gene copy than vector controls.
To confirm and extend the correlation between increase in HuD expression and loss of N-myc genes, a second cell line, SMS-KAN, was stably transfected, cloned and maintained under the same conditions as described above. SMS-KAN cells are monozygous for HuD and have 150-fold amplification of N-myc genes in DMs. After verifying an increase in HuD expression in the HuD-transfected cells, the clones were assayed for changes in N-myc gene copy number using semiquantitative PCR and florescence in situ hybridization (FISH). The results confirmed the earlier findings -the HuDtransfected SMS-KAN cells had 2.8-fold fewer N-myc genes than the vector-transfected controls (Figure 4a ) and, although the signals were too numerous to count, distinctly fewer N-myc genes by FISH (Figure 4b,c) .
Modulation of N-myc gene copy number and mRNA expression in cells transfected with antisense HuD In a second approach to test our hypothesis, we examined whether reduction in HuD expression could select for neuroblastic cells containing increased numbers of N-myc genes, that is, cells exhibiting gene gain or amplification. Neuroblastic SH-SY5Y cells, with three copies of N-myc and two copies of the HuD gene, were transfected with a plasmid containing a portion of HuD cDNA sequence in an antisense orientation (Lazarova et al., 1999) . Six antisense-HuD-transfected and three vector-transfected clones were analysed for HuD and Nmyc expression levels, neuroblastic marker proteins, as well as N-myc amplification status. Each of the antisense-HuD-transfected clones were thereafter maintained on at least three different concentrations of G418. All clones remained neuroblastic, as confirmed both morphologically and biochemically (data not shown). Compared to vector-transfected clones, HuD mRNA, and Hu protein levels are reduced three-fourfold in the antisense-HuD clones ( Figure 5 and Table 5 ), and Nmyc mRNA levels are decreased almost twofold. Semiquantitative PCR analysis of N-myc gene copy number with primers to intron 1 indicates that antisense transfectants have accumulated additional copies of Nmyc genes (Figure 6a and Table 5 ). The observed gain occurred independently in at least five of the six individual clones, with a gain in gene copy number from B2 to >5 copies/haploid genome. These measurements were confirmed using primers to N-myc exon 3 (data not shown). Additionally, FISH analysis showed an increase in the gene copy number of antisense transfected cells (4.5970.09; two clones, n ¼ 200) versus vector-transfected controls (2.7270.05; two clones, n ¼ 200; Po0.0001) (Figure 6b, c) . Less than 5% of Gene copy number (mean7s.e.m.) of 2-13 independent samples was determined by semiquantitative PCR using primers to the first intron of the N-myc gene. For simplicity, gene copy number for vector controls was set to 1.
Loss of one HuD allele selects for N-myc amplification KB Grandinetti et al the transfected cells were tetraploid as determined by cytogenetic analysis, thus ruling out the occurrence of increased N-myc gene copy number due to polyploidy.
Discussion
Amplification of the N-myc proto-oncogene was the first genetic abnormality useful in the prognosis of neuroblastoma. More recent evidence has shown the loss of chromosome 1p to be predictive of disease course as well (Caron et al., 1996; Bown et al., 1999) . We show here that these genetic events are functionally linked and propose that it is the haploinsufficiency of the RNAbinding protein, HuD, resulting from loss of one allele on chromosome 1p, that is instrumental in development of N-myc amplification in neuroblastoma. The major findings described in this paper -(1) N-myc amplification and loss of one 1p occur together in neuroblastoma cell lines, (2) introduction of HuD cDNAs into cells with one HuD allele results in decreased N-myc gene copy number, and (3) reduction of HuD levels in stable antisense transfectants results in N-myc gene amplification -strongly support this hypothesis.
The present study shows that all of the N-myc amplified cell lines that we examined have lost all or a portion of one chromosome 1p. Caron et al. (1996) and Bown et al. (1999) observed the association between these two events in neuroblastoma tumors as well. Both studies did note that not all cells that had lost 1p were N-myc amplified. Further classification of the missing regions of chromosome 1 (Takeda et al., 1994) lends support to the correlation between N-myc amplification and loss of the HuD allele at chromosome 1p34. Loss of a large region between 1p32 and the terminus of the short arm predicts a poor outcome, whereas smaller, interstitial regions of loss around 1p36 are indicative of a more favorable long-term survival. An interesting exception described in our results is the SMS-MSN cell line derived from a stage 4 tumor (Reynolds et al., 1988) .
While it exhibits N-myc amplification, cytogenetic analysis reveals two apparently normal copies of chromosome 1. However, our Southern and PCR analyses indicate that it is monoallelic for HuD. This result would suggest that it is the loss of the HuD gene, and not a putative tumor suppressor gene contained in the 1pter-1p32 region, that is, selective for the protooncogene's amplification.
In another study, expression levels of HuD (and Hel-N1) were compared with N-myc amplification status in both neuroblastoma cell lines and tumors (Ball and King, 1997) . They detected expression of both Hufamily genes in all cell lines and 35 of 36 neuroblastoma tumor samples examined. Although levels of Hel-N1 in N-myc amplified and nonamplified tumors were not statistically different, there was a significant downregulation of HuD with amplification, consistent with our findings. Moreover, high levels of HuD correlated with favorable tumor stage.
The genetic events that lead to formation of neuroblastoma tumors, as well as to the genetic instability that predisposes cells to chromosome breakage and gene amplification, are as yet unidentified. However, it appears that loss of one HuD allele may help to explain the development of N-myc amplification seen in those 30% of neuroblastoma tumors with the worst prognosis. These studies provide a mechanistic explanation for the correlation between loss of a portion of chromosome 1p, specifically one allele of HuD, and N-myc amplification. From these results, the following model is proposed. The Hu-family of RNA-binding proteins, to which HuD belongs, has significant similarity to the Drosophila melanogaster proteins ELAV (embryonic lethal abnormal vision) and sexlethal (Szabo et al., 1991 , King et al., 1994 , both of which function in alternative splicing (Baker et al., 1989; Koushika et al., 1996) . The similarity to these splicing factors suggests, at the very least, an essential nuclear role for HuD. We and others (Lazarova et al., 1999; Sivak et al., 1999; Manohar et al., 2002) have shown that HuD binds specifically to AU-rich regions within both the 3 0 UTR and first intron of the N-myc premRNA. In cells committed to a neuronal lineage, the binding of HuD stabilizes the nascent message and allows more transcripts to be spliced/processed into mature mRNA (Lazarova et al., 1999) . By contrast, in non-neuroblastic variants that do not express HuD, the transcript is quickly degraded, markedly reducing the amount of mature N-myc mRNA. Consequently, the loss of one HuD allele, as documented here and elsewhere (Caron et al., 1996) , creates a bottleneck in the processing of the N-myc transcript. As increased expression of N-myc has been hypothesized to provide a growth advantage in the neuroblastic population (Lutz et al., 1996) , those cells that have additional copies of the N-myc gene have a selective growth advantage.
In the present study, we have shown that changes in HuD expression can and do directly alter N-myc expression and modulate gene copy number. By what mechanisms can these changes be effected? Extrusion of amplified N-myc genes has been reported for human Loss of one HuD allele selects for N-myc amplification KB Grandinetti et al neuroblastoma tumors (Valent et al., 2001 ) and loss of DMs and HSRs comprising amplified drug-resistance genes has been observed in cultured cells during growth in drug-free medium (i.e., in absence of selection pressure) Meyers et al., 1985) . Although mechanism was not considered in our study, loss of N-myc genes probably results from unequal distribution of DMs during mitosis or unequal crossingover involving HSRs and subsequent selection for the progeny with fewer gene copies. Our evidence from transfection experiments indicates that loss of one HuD allele is an important permissive factor in the gain of N-myc genes in neuroblastoma cell lines. However, the loss of a HuD allele may not be the only factor. One intriguing aspect of N-myc amplification is that of scale -amplified tumors express as much as 150-fold more of the oncoprotein than do nonamplified neuroblastomas. Perhaps it is the loss and consequent decrease in expression of one or more additional genes also in the region of loss of chromosome 1 (such as L-myc, TP73, or CHD5) or coamplification of other genes within the N-myc amplicon that provides the necessary selection pressure for high-level amplification. Clearly, additional studies are required to clarify the cause and consequences operating in this still enigmatic cancer.
Materials and methods
Cell culture and HuD transfections Cell lines established from 12 different human neuroblastoma tumors and/or subpopulations and clones were cultured as previously described (Spengler et al., 1997) . The sense HuD construct, containing the full length HuD cDNA inserted into the pcDNA3 vector, and the antisense construct, comprising 197 nucleotides of the HuD stringer region inserted in the pbAct vector, have been described (Lazarova et al., 1999) . Control cultures were transfected with vector alone. Cells were transfected using Lipofectamine PLUS (Invitrogen, Carlsbad, CA), selected with Geneticin (G418) (Invitrogen, Carlsbad, CA) and cloned as described previously (Lazarova et al., 1999) .
Karyotype analysis GTG-banded metaphase cells were prepared as previously described (Ross et al., 1983) . Chromosome band nomenclature follows the standards outlined in ISCN (1995) .
Western blot analysis
Protein homogenates from cells in exponential growth phase were prepared by the method of Ikegaki et al. (1986) . Western blots prepared by standard techniques were probed with monoclonal antibodies to chromogranin A or neurofilament 160 (Chemicon, Temecula, CA), or polyclonal antiserum to human Hu antigens (kindly provided by Dr M Rosenfeld, University of Pennsylvania, Philadelphia, PA). Quantification was done by densitometric scanning and the amount of protein normalized to heat shock protein 72/73.
Analysis of gene copy number and mRNA steady-state levels Gene copy numbers were estimated using Southern blot analysis of EcoR1-restricted high molecular weight DNA as well as multiplex PCR analysis. Owing to the small, approximately twofold differences being measured and normal biological variation, each Southern blot was run with two to four independent SH-SY5Y DNA preparations as controls; the mean of all the controls was set to two and the relative gene copy numbers quantified for each DNA. Blots were probed at high stringency with cDNA sequences encoding, in part, the unique stringer region of HuD and the third exon of N-myc (pCRII-NM) (Lazarova et al., 1999) . Probes were labeled with the RTS Radprime DNA labeling system (Invitrogen, Carlsbad, CA) using [a-32 P]-dCTP (Perkin Elmer, Boston, MA). Extent of hybridization was visualized on Kodak XAR film and quantified by scanning densitometry. Amounts were normalized for loading variations to those obtained for g-actin and/or GAPD. Multiplex PCR DNA amplification was done by the method of Chamberlain et al. (1988) , as described by Henegariu et al. (1997) . Gene copy number for HuD, Hel-N1, or N-myc was measured using semi-quantitative or multiplex PCR and normalized to b-actin. 0 . mRNA steady-state levels were quantified using Northern blot and semiquantitative reverse transcriptase PCR (RT-PCR) analyses. RNA was isolated by published procedures (Chomczynski and Sacchi, 1987; Lazarova et al., 1999) from cells in exponential growth phase and Northern blots done using standard techniques. For RT-PCR, RNAs were reverse-transcribed and the resulting cDNAs amplified using the GeneAmp system (Perkin Elmer, Foster City, CA), with the primers described above. For negative controls, reactions were performed without enzyme. Products were resolved on 1% agarose gels in 0.5 Â TRIS-borate-EDTA buffer containing 0.1 mg/ml ethidium bromide and photographed on Polaroid 667 film. Amount of nucleic acid was estimated by scanning densitometry and normalized to levels of b-actin or GAPD.
Florescence in situ hybridization SMS-KAN HuD-and vector-transfected cells and SH-SY5Y antisense-HuD-and vector-transfected cells in logarithmic growth phase were prepared by standard cytogenetic procedures. Slides were allowed to dry for at least 18 h prior to hybridization. Denaturation and hybridization were done with the LSI N-myc Spectrum Orange probe (Vysis, Downers Grove, IL) as described by the manufacturer. DAPI II counterstain (Vector Laboratories, Burlingame, CA) was added and the slide incubated in the dark for 30 min at 41C before viewing. In all, 100 cells from two independent clones were counted by two different people for both antisense-HuD and vector-transfected cells. Statistical significance was determined by Student's t-test.
